@entity908 -kinase and dialysis XXXX , a helpful tool for stratifying cardiovascular risk?

@entity1 @entity1095 @entity6 @entity908 @entity299 @entity65
BACKGROUND AND AIMS: Hemodialysis @entity1 have an enhanced risk for @entity65 . Cardiac biomarkers provide useful information for stratifying their risk. However the prognosis value of @entity908 kinase MB isoenzyme (CKMB) has not yet been validated in this population. The aim of the present study is to determine the predictable value of CK-MB in hemodialysis. METHODS: A cohort of 211 hemodialysis @entity1 (58.3% male, median age 73 (60-80) years) were followed for 39 (19-56) months. Cardiac biomarkers including CKMB were recorded at baseline. Factors associated to CKMB and prognosis value of this biomarker was studied. RESULTS: The median value of CKMB was 1 (1-2) ng/mL with no @entity1 exceeding normal laboratory values. Previous @entity299 , @entity6 , @entity1095 were associated with higher levels of CKMB. Ninety-four @entity1 (44.5%) @entity65 were recorded. CKMB levels >= 2ng/mL was independently associated to @entity65 during the follow up after adjusting. Adding CKMB to a model including several variables for predicting @entity65 , resulted in 17% improvement in risk discrimination (IDI) with a relative IDI of 9.9% (p=0.04). CONCLUSIONS: CKMB is a good marker for stratifying cardiovascular risk in hemodialysis @entity1 and adds prognosis information to other well known independent predictors for @entity65 .
